Study definition provided in at least title, abstract or main paper
|
74 (64)
|
Title, abstract, and main paper
|
9 (12)
|
Abstract and main paper
|
16 (22)
|
Title and main paper
|
17 (23)
|
Title and abstract
|
1 (1)
|
Title
|
5 (7)
|
Abstract
|
7 (9)
|
Main paper
|
19 (26)
|
Country of study
|
USA
|
39 (34)
|
UK
|
18 (16)
|
Asia
|
18 (16)
|
Europe
|
14 (12)
|
Canada
|
11 (9)
|
Australia
|
7 (6)
|
Africa
|
6 (5)
|
Middle East
|
2 (2)
|
Panama
|
1 (1)
|
Type of intervention
|
Programs (e.g. multifaceted)
|
41 (35)
|
Policy (e.g. regulatory)
|
32 (28)
|
Health systems
|
25 (22)
|
Guidelines
|
19 (16)
|
Financial
|
19 (16)
|
Behavioural
|
15 (13)
|
Sales and dispensing
|
1 (1)
|
Level of intervention
|
Hospital
|
73 (63)
|
Hospital department
|
22 (19)
|
Individual
|
17 (15)
|
GP practices
|
3 (3)
|
Pharmacy
|
1 (1)
|
Participants
|
Health professional
|
92 (79)
|
Disease
|
30 (26)
|
Occupational
|
3 (3)
|
Population
|
1 (1)
|
Data source
|
Hospital data
|
64 (55)
|
Health records
|
27 (23)
|
National data
|
26 (22)
|
Insurance data
|
11 (9)
|
Other
|
3 (3)
|
Type of outcome
|
Continuous
|
66 (57)
|
Rate
|
38 (33)
|
Binary
|
11 (9)
|
Count
|
1 (1)
|
Frequency
|
Monthly
|
74 (64)
|
Quarterly
|
23 (20)
|
Yearly
|
14 (12)
|
Weekly
|
2 (2)
|
Othera
|
3 (3)
|
Number of data points - median (25th,75th centile)
|
Pre-intervention
|
18 (12–32)
|
Post-intervention
|
19 (12–34)
|
Ratio of pre/ post-intervention data points
|
1 (1–2)
|
Transition period (n = 20)
|
3 (1–9)
|
Other data points that were accounted for (n = 3)
|
2 (2–8)
|